in resting lymphocytes indicates that FasR might primarily be involved in activation-induced cell death of peripheral lymphocytes and suggests that cellular sensitivity may involve mechanisms other than those relating to the presence of FasR.
Apoptosis is associated with the activation of a number of genes that mediate the transition from quiescence to proliferative growth.I7 This activation frequently leads to an abortive cell cycle that fails to enter S phase," although cases exist that demonstrate induction of apoptosis in S or G2
In some cell lines, treatment with agents that arrest cells in early G1 phase offers protection from a p o p t o s i~,~~ while transfection with molecules that stimulate DNA replication, such as E1A or c-myc, promotes this re~ponse.'~~*~ These observations suggest that there may be an association between the action of FasR-mediated signals and a specific phase of the cell cycle. However, little is known about the action point of FasR-mediated signals. In the present study we have demonstrated that the enhancement of cell proliferation by growth-promoting cytokines, such as interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF), could modulate cellular susceptibility toward FasR-mediated apoptotic cell death in acute myelogenous leukemia (AML) cells. Furthermore, in order to define cell cycle restriction points for triggering of FasR-mediated apoptosis, we have established a FasR', apoptosis-sensitive leukemic cell line, MML-1. We found that cell cycle arrest in early G1 (GlA) phase could render MML-1 cells resistant to FasR-mediated apoptotic cell death. Abbreviation: ND, not determined. Flow cytometric analysis was performed to determine the expression of FasR. The results were expressed as RFI. Thymidine incorporation was determined in cultures in the presence of anti-Fas MoAb (10. 100, and 1,000 ng/mL) as a measure of cell proliferation. Values indicate mean cpm. The results were compared with the values in AML cell culture with isotype-matched control MoAb (1.000 ng/mL). Significant inhibition of thymidine uptake is indicated by underline. The AML cells were classified according to the FAB cytology.
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(case W 1 listed in Table 1 ) with AML-M1 expressing both myeloid (CD13, CD15, and CD33) and lymphoid (CD19) markers at the time of diagnosis. Cells were suspended in RPMI 1640 medium with 10% FCS (complete medium) and cultured in an atmosphere of 95% air and 5% CO2, at 37°C. Cells grew without any cytokines or conditioned medium. MML-l cells were established by repetitive cloning. The surface phenotype of "L-1 cells was quite similar to that of fresh leukemic cells. The phenotype and characteristics of MML-l cells have been stable for 2 years since their establishment.
" L -1 cells were arrested in early G1 (GlA) phase with phorbol 12-myristate 13-acetate (PMA, 10 nmoVL) or thymidine (1 to 50 mmoVL). Additionally, MML-l cells were arrested in early S phase with 5-fluorouracil (5-FU, 10 pmoVL). After washing three times, cells were further incubated in complete medium. MML-1 cells were harvested at the indicated times and used for subsequent experiments. Cell viability assessed by trypan blue dye exclusion was more than 95% in all experiments.
Antibodies and reagents. Anti-Fas monoclonal antibody (clone CH-1 1, mouse IgM) was obtained from Medical & Biological Laboratories (Nagoya, Japan). Affinity-purified phycoerythrin (PE)-conjugated goat anti-mouse IgM antibody was purchased from TAG0 Immunologicals (Burlingame, CA). The human recombinant L 3 and GM-CSF were from Genzyme Corporation (Boston, MA). H-7, a protein kinase C (PKC) inhibitor was from Seikagaku CO (Tokyo, Japan). Thymidine, PMA, 5-FU, ribonuclease A (RNase A), deoxyribonuclease I (DNase I), 7-amino-actinomycin D (7-AAD). pyronin Y, saponin, and proteinase K were obtained from Sigma Chemical CO (St Louis, MO), and propidium iodide (PI) from Calbiochem (La Jolla, CA).
Cell proliferation assay. Proliferation of leukemic blasts was evaluated by measuring ['H] thymidine (TdR, 925 GBq/mmol, Amersham Corp, Arlington Heights, L) incorporation.*' Blast cells isolated from patients' BM (3 X 105/mL) were plated in 100 pL of complete medium in round-bottomed 96-well microtiter plates (Costar, Cambridge, MA) and incubated with IL-3 (1,OOO U/mL), GM-CSF ( 1, OOO UlmL) and control without cytokine supplementation. At 24 hours after plating cells, anti-Fas monoclonal antibody (MoAb) was added at the concentrations of 10 to 1, OOO ng/mL. Colorimetric DNA-fragmentation assay. Apoptosis was measured by flow cytometry according to a previously published procedure with minor modification^.^^,^^ In order to record DNA histogram, about IO6 cells were pelleted, resuspended in 200 pL PBS, and fixed rapidly with 2 mL 70% ice-cold ethanol. Cells were centrifuged from the fixative, resuspended in 1 mL PBS containing 10 pg/mL PI, 100 pg/mL ribonuclease A, and incubated at 37°C for 30 minutes. The excitation wavelength in the cytometer was 488 nm and orange (FL-2, 585 nm) fluorescence was recorded with FACScan flowcytometer. The apoptotic cell nuclei (sub-G1 peak in the DNA fluorescence histogram) was calculated using LYSYS software (Nippon Becton Dickinson). Data were expressed as the Simultaneousjow cytometric analysis of DNA and RNA content. Detailed cell cycle analysis based on cellular DNAlRNA content was performed using simultaneous flow cytometric analysis of DNA and RNA content, as described previously with minor modificati on^.^"^' Briefly, one million cells fixed with 70% ice-cold ethanol were centrifuged from the fixative, washed with PBS containing 0.5% bovine serum albumin (BSA), and suspended in 1 mL nucleic acid staining solution (NASS pH 6.0; 0.15 m o m NaCI, 0.1 moVL phosphate-citrate buffer, 5 mmoVL sodium EGTA and 0.5% BSA) supplemented with 0.004% saponin. Then cells were incubated with 20 pmol/L 7-AAD for 30 minutes at room temperature. After incubation with DNA dye, cells were cooled on ice for at least 10 minutes, and reacted with 5 pmoVL pyronin Y for an additional 10 to 60 minutes at 4°C. Simultaneous orange (585 nm) and red ( M 5 0 nm) fluorescence emission was recorded with FACScan flowcytometer and analyzed using CellFit and LYSIS software (Nippon Becton Dickinson). The intensity of 7-AAD red fluorescence (K-3) was linearly proportional to the content of DNA per cell and the intensity of pyronin Y orange fluorescence ( K -2 ) was correlated with RNA content. The specificity of DNA and RNA staining was evaluated by preincubation of permeable cells with DNase I and RNase A. Over 95% of the red fluorescence and over 90% of the orange fluorescence were sensitive to DNase I and RNase A, respectively. Cells with increased RNA content, defined as G1 cells, were calculated on the basis of multichannel analysis data, setting the GO-G1 boundary on the basis of RNA histograms, as described previo~sly.~' The borderline between cells with moderately (GlA) and markedly increased RNA content (G1 B) represented the minimal RNA content of the S-phase cell population.
DNA extraction and agarose gel electrophoresis. Cells (1 to 2
x lo5) were washed once with ice-cold PBS, pelleted, and resuspended in 400 pL lysis buffer (pH 7.5; 10 mmol/L Tris, 1 mmol/L EDTA, 0.5% SDS, 100 pg/mL proteinase K). The cell lysate was mixed gently and incubated at 37°C overnight. After incubation, NaCl was added to a final concentration of 150 mmoUL. Nucleic acids were extracted twice with equal volume of phenollchlorofod isoamyl alcohol (25:24:1). Then the samples were centrifuged for 10 minutes at 12,00Og, and aqueous phase of each sample was transferred to another tube. The nucleic acid solution was incubated for 2 hours at 37°C with 100 pg/mL of ribonuclease A. DNA was precipitated with 1 mL of ice-cold ethanol at -20°C overnight. The samples were then electrophorated in 2% NuSieve agarose gel ( M C BioProduct) in 90 mmoVL Tris, 90 mmoVL boric acid, and 2 m o l / L EDTA buffer, pH 8.0. Gels were stained with ethidium bromide thereafter.
GM colony-forming assay. Human BM was obtained from informed healthy volunteers and was density-separated on Ficoll-Hypaque. Low-density cells (lO'/mL) were suspended in RPM1 1640 medium with 10% FCS, and cultured with or without IL-3 (1,000 U/mL), GM-CSF (1,000 UlmL), control MoAb, and anti-Fas MoAb (1,000 ng/mL) for 3 or 7 days. Subsequently, cells (I05/mL) were plated in 1 mL IMDM with 30% FCS, 100 U/mL GM-CSF, and 0.88 methylcellulose in the presence of either control MoAb or anti-Fas MoAb. Aliquots of 1 mL were plated in duplicate in tissue culture plates (Falcon) for 7 and 14 days under fully humidified conditions in an atmosphere of 5% CO2 in air, at 37°C. Colonies of >40 translucent cells, counted under an inverted microscope, were regarded as GM colony-forming units (CFU-GM). The results were given as mean values of duplicate cultures per IO5 cells.
RESULTS

FasR (CD95) expression on fresh AML cells.
We first analyzed FasR expression on AML cells obtained from 18 patients by flow cytometric immunofluorescence analysis. As shown in Table 1 , fresh AML cells were all positive for FasR, although the values of RFI (range: 1.83 to 14.79) were variable among tested samples. The histograms from the flow cytometry data (Fig 1) indicated that a relatively low RFI was not due to bright expression of CD95 by a minor cell population, but due to dim expression of CD95 by all leukemic cells. No distinct difference was identified in the intensity of FasR expression, after AML cells were cultured in the presence of IL-3 or GM-CSF for 3 days (data not shown).
FasR-mediated growth inhibition in AML cells. To investigate the effect of anti-Fas MoAb on proliferation of AML cells, blast cells collected from patients were cultured for 3 days to achieve maximal stimulation in vitro and DNA synthesis was measured in the presence of anti-Fas MoAb ( Table 1) . In all patients the rate of thymidine uptake exceeded the (irradiated) background value and fresh AML cells showed spontaneous proliferation with isotype-matched control MoAb. A significant inhibition of DNA synthesis was observed in AML cells from 10 of 20 cases, when cells were cultured with anti-Fas MoAb to achieve concentrations as low as 100 to 1,000 ng/mL. The suppression of DNA synthesis by anti-Fas MoAb was dose-dependent. However, in half of the AML cases (a refractory group), DNA synthesis was not inhibited with the treatment of anti-Fas MoAb.
In addition, the effects of anti-Fas MoAb on the DNA synthesis of AML cells were assessed in the presence of optimal concentrations of human recombinant IL-3 and GM-CSF (Fig 2) . In most cases, cell proliferation was further enhanced by exogenous IL-3 and GM-CSF, as previously reported.z8 Cell cycle analysis of blast cells was performed in parallel with cell proliferation assay and consistently demonstrated the increased percentage of blast cells in S phase (Fig 3) . More interestingly, AML cells from five patients (cases 8, 9, 10, 12, and 20 in a Fas-refractory group) could become sensitive to FasR-mediated growth inhibition, when cells were stimulated with IL-3 or GM-CSF before the addition of anti-Fas MoAb. AML cells from two patients (cases 2 and 6 in a Fas-sensitive group) were equally susceptible to FasR-mediated growth inhibition, in cultures with IL-3, GM-CSF, and control medium. FasR-mediated DNA fragmentation in AML cells. TO clarify whether FasR-mediated growth inhibition in AML cells is associated with DNA fragmentation, the most characteristic biochemical feature in apoptosis, AML cells treated with anti-Fas MoAb were analyzed with colorimetric DNA fragmentation assay ( Table 2) . We found that the inhibition of DNA synthesis induced by anti-Fas MoAb was accompanied by the increase of apoptotic nuclei in sub-G1 fraction, which suggested the induction of DNA fragmentation. In a Fas-sensitive group, there was no significant difference in A sub-G1 fraction between control and cytokine-supplemented LOG FLUORESCENCE cultures. In contrast, when AML cells from Fas-refractory cases (cases 8, 9, 10, 11, 12, and 20) were cultured in the presence of IL-3 or GM-CSF, a distinct increase of A sub-G1 fraction was demonstrated with the addition of anti-Fas MoAb.
The representative DNA histograms with the percentage of apoptotic nuclei in sub-G1 fraction were shown in Fig 3. Addition of anti-Fas MoAb to AML cells from a patient (case 12) had no effect in control culture. However in cytokinesupplemented cultures, the percentage of cell nuclei in sub-G1 fraction apparently increased in the presence of anti-Fas MoAb. It is also of note that the percentage of S-phase fraction was clearly elevated in the presence of IL-3 or GM-CSF, suggesting the further activation of G1 + S transition. Bone marrow colony-fomzing assay. We have performed GM colony-forming assay to clarify whether antiFas MoAb could also trigger killing of bone marrow progenitor cells exposed to cytokines (Table 3) . When marrow cells were first stimulated with IL-3 or GM-CSF for 7 days in suspension, the postculture number of day 7 of 14 CFU-GM apparently increased. However, anti-Fas MoAb did not reduce the number of CFU-GM from stimulated marrow cells. It is of interest that when marrow cells were pretreated with anti-Fas MoAb in the presence of IL-3 or GM-CSF, quantitation of CFU-GM demonstrated no significant difference in frequency, either. Similar results were obtained, using marrow cells precultured with cytokines for 3 days (data not shown).
FasR-mediated apoptosis in MML-l cells. A Fas-sensitive leukemic cell line, MML-1 was established from a patient (case MO1 listed in Table l ). This cell line provided an experimental model for analyzing the molecular events that contribute to the induction of FasR-mediated apoptotic cell death. Light microscopy showed a typical apoptotic morphology with fragmented nuclei and chromatin condensation in treated MML-1 cells (Fig 4) . Agarose Cell cycle analysis of MML-l cells treated with anti-Fas MoAb. Cell cycle analysis was performed to determine whether any alteration in cell cycle progression might affect the induction of FasR-mediated apoptosis in MML-I cells (Table 4 and Fig 5) . When MML-I cells were treated with PMA (10 nmol/L), the number of cells in GI phase significantly increased. This was associated with a reduction in numbers of cells in S phase, followed by a decrease of cells in GUM phase. In the presence of anti-Fas MoAb, the increase of apoptotic nuclei in sub-G1 fraction became evident 3 hours after the addition of MoAb. Interestingly, when MML-1 cells were preincubated with PMA, the appearance of sub-GI peak was inhibited. It is of note that neither alter- 
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ation in cell cycle progression nor increase of sub-G1 apoptotic nuclei were observed in MML-1 cells treated with H-7, a potent PKC inhibitor. The effect of PMA was timedependent in that sub-G1 fraction of apoptotic nuclei, measurable at 12 hours, was not detected after 24 hours. Serial analysis of the cell cycle clearly indicated that the decrease of cells in S phase was in parallel with the reduction in the percentage of apoptotic nuclei. In addition, cell cycle arrest induced by PMA could be restored in the presence of H-7. MML-1 cells treated with PMA plus H-7 were clearly susceptible to cell death and DNA fragmentation induced by anti-Fas MoAb.
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Similar results were obtained when MML-l cells were treated with thymidine at the concentration of 1 to 50 mmoV L. Additionally, when two T-lymphoblastoid cell lines, CCRF-CEM-C7 and MKB-1 (both of which were sensitive to FasR-mediated apoptosis), were pretreated with PMA and thymidine, respectively, cell cycle arrest in G1 phase was induced and FasR-mediated apoptosis was similarly inhibited (data not shown).
Treatment of MML-1 cells with 5-FW promoted the arrest in early S phase (Fig 6) . When 5-FU-treated cells were washed and cultured for an additional 24 hours, a significant increase of cells in middle S phase was observed and the rate of thymidine incorporation into 5-FU-treated cells also increased (mean 2 SD: 11,085 t 985 cpm in control cells + 24,398 t 1267 cpm in 5-FU-treated cells). However, we found that MML-1 cells pretreated with 5-FU were equally susceptible to the induction of apoptosis by anti-Fas MoAb. The percentages of apoptotic nuclei after 6 hours treatment with anti-Fas MoAb were similar to those of controls, even though the numbers of cells in early S or middle S phase significantly increased.
Simultaneous DNMRNA quantification of MML-I cells. To better evaluate an association between cell cycle arrest and FasR-mediated apoptosis, MML-l cells treated with anti-Fas MoAb were analyzed using a DNA/RNA double staining technique. Cells incubated with PMA (10 nmolL) for 24 hours ceased proliferation and were predominantly arrested with a G1 DNA content, although a few cells remained in a S or G2A4 phase (Fig 7) . After incubation with PMA for 48 hours, more cells were present in GlA, the low-RNA G1 compartment, and fewer in the G1B compartment. Thus, suppression of cell proliferation in these cultures resulted in a change in the G l N G l B cell ratio toward G1A. Anti-Fas MoAb, present in cultures at 1,000 ng/mL for 3 hours, induced a remarkable increase of cells in the sub-G1 compartment with lower DNA and RNA values. As shown by the continuity of the sub-G1, G1, and S clusters, cells in G1 and early S phase most probably entered the sub-G1 compartment. Incubation of MML-1 cells with PMA before the addition of anti-Fas MoAb, clearly reduced the number of cells in the sub-G1 fraction. Note that a decrease of cells in the sub-G1 compartment was paralleled by a change in the G l N G l B cell ratio, with more cells now residing in the G1A compartment.
Similar results were obtained, when MML-l cells were treated with thymidine at concentrations of 1 to 50 mmoY L. The transition of cells from G1 A to GIB phase was significantly inhibited. In the cultures with anti-Fas MoAb, the number of apoptotic nuclei in the sub-G1 fraction was reduced in parallel with a decrease of cells in the G1B compartment. The appearance of the sub-G1 fraction was accompanied by the most significant loss of cells in the G1B compartment. Although the majority of MML-1 cells, treated with 10 mmoVL thymidine for 24 hours, were arrested in the G1A phase, a few cells entered the G1B phase. These cells in the G1B compartment were selectively diminished in the culture with anti-Fas MoAb.
DISCUSSION
The growth and death of hematopoietic cells are modulated by the external signals that stimulate apoptosis via the Abbreviation: ND, not determined. Colorimetric DNA-fragmentation assay was performed to determine the fraction of apoptotic cell nuclei (sub-G1 fraction). AML cells were cultured with isotype-matched control MoAb for 3 days to evaluate baseline DNA fragmentation. Blast cells were also cultured with anti-Fas MoAb (1,000 ng/mL) either in complete medium without cytokine supplementation or in the presence of 11-3 (1,000 U/mL) or GM-CSF (1,000 U/mL). Data of FasR-mediated apoptosis were expressed as the percentage of Asub-G1 fraction. The AML cells were classified according to the FAB cytology.
cell surface molecules. FaslUCD95 has now emerged as an important cellular component that mediates an apoptotic cell death in hematopoietic cells. In the present study, FasW CD95 was shown to be expressed on a majority of AML cells, although the intensity of expression was variable. Our results contrasted with those of previously published studi e~,~~ which found FasR on only a small minority of AML cases. In these studies, samples were analyzed by indirect immunofluorescence assay using a fluorescence microscope, whereas expression of FasR was assessed by flow cytometry in our study. Although the apparent reason was unknown, we assumed that this discrepancy could be due to differences in staining methods, or in criteria used to define FasR positivity. We also found that the cross-linking with anti-Fas MoAb could induce growth inhibition and DNA fragmentation in AML cells. But the sensitivity of FasR-positive blast cells to apoptotic action of anti-Fas MoAb has been observed to vary from cell to cell. Some AML cells were sensitive to the apoptosis-inducing ability of anti-Fas MoAb, and others were refractory to this MoAb. There existed no apparent correlation between the sensitivity to FasR-mediated cell death and FasR density on the cell surface. The failure of anti-Fas MoAb to trigger cell death in insensitive AML cells may involve mechanisms other than those relating to the presence of FasR.
Substantial spontaneous proliferation of AML cells has Normal marrow cells were first cultured in suspension with or without IL-3, GM-CSF, anti-Fas MoAb, and control MoAb for 7 days. Subsequently, cells were collected and plated in methylcellulose containing GM-CSF in the presence of anti-Fas MoAb or control MoAb. CFU-GM colonies were counted on days 7 and 14. The data represent mean 2 SD of four independent experiments.
For For been demonstrated in all patients studied. The rate of thymidine uptake exceeded the background values, as shown in Table 1 . However, previous studies revealed that blasts from at least one-third of AML patients exhibited very low spontaneous proliferation, when cells were cultured in serum-free m e d i~m .~~. '~ In contrast, Rogers et a1 showed a relatively high rate of spontaneous thymidine uptake, when AML cells were incubated in culture medium containing 10% FCS.j7 Thus the discrepancy in spontaneous proliferation of AML cells might be due to the differences in culture condition.
This study described a close association between a special phase of the cell cycle and apoptotic cell death induced by cross-linking of FasR molecule on leukemic cells. First, we demonstrated that cellular susceptibility to apoptotic cell death by anti-Fas MoAb could be induced in blast cells obtained from AML patients, when cells were stimulated by IL-3 or GM-CSF. Studies have shown that the proliferative effect of hematopoietic growth factors including IL-3 and GM-CSF drives on leukemic cells in G1 pha~e.*~,~*-~' Since IL-3 and GM-CSF would mediate the transition from quiescent GO/GlA phase to proliferative G1B phase and growth inhibition of anti-Fas MoAb in AML cells was potentiated in the presence of these cytokines, G1 A + G1B transition might be necessary for the induction of FasR-mediated apoptotic cell death. In contrast, the data of colony-forming assay indicated that anti-Fas MoAb could not trigger apoptotic cell death of myeloid progenitor cells stimulated with growthpromoting cytokines. This resistance might be due to negative expression of FasWCD95 on progenitor cells, or a failure in intracellular transduction of FasR-triggered signals. Apparently, further studies should be undertaken to investigate the contribution of FasR-FasL system to bone marrow hematopoiesis.
Because cell cycle progression induced by IL-3 and GM-CSF enhanced FasR-mediated growth inhibition, we assumed that FasR-mediated inhibitory signals could be transduced into AML cells at the time they entered G1B compartment. Such cells could undergo an apoptotic process as measured by flow cytometry. In order to determine a specific phase of the cell cycle for FasR-mediated apoptotic cell death, we further investigated whether the sensitivity to antiFas MoAb-induced apoptosis could be affected by any alteration in cell cycle progression, using a Fas-sensitive cell line, MML-1. The studies with PMA and thymidine clearly revealed that cells in G1A phase were refractory to FasRmediated apoptosis and the selective and rapid loss of cells in G1B compartment was quite characteristic. Moreover reversible arrest in early S or middle S phase with 5-FU could neither enhance nor inhibit FasR-mediated apoptosis in MML-1 cells, indicating that cells in S phase were also insensitive to FasR-mediated apoptosis. Taken together it has been strongly suggested that FasR-mediated apoptotic signals could be transduced into cells in G1B compartment. Moreover we assumed that these results would be generally applicable to apoptosis triggered through FasWCD95, because similar results were obtained using two sensitive Tlymphoblastoid cell lines. A role of protein kinase C (PKC) in suppression of apoptosis has been documented in thymocytes?1 B lymphoma cells:' and L-3-dependent cell lines?3 It is of note that H-7, a potent PKC inhibitor did not have any effect on growth of MML-1 cells, but could antagonize the protective effects as well as cell cycle arrest induced by PMA. These results suggested that the inhibition of FasR-triggered apoptosis and cell cycle arrest in G1 phase could be mediated via activation of PKC rather than down modulation. The activation of PKC with PMA might be sufficient to protect MML-1 cells from FasR-mediated apoptosis, although unlikely because thymidine could also suppress FasR-mediated apoptosis and both PMA and thymidine were capable of inhibiting the transition from G1A to G1B phase. It is more likely that GlA -+ G1B transition would be required for the effective induction of FasR-mediated cell death.
In Fas-refractory AML, cases, which exhibited substantial spontaneous proliferation, blast cells entering S phase would proceed in the cell cycle, but be insensitive to FasR-mediated apoptosis. When AML cells were incubated in culture medium without cytokines for a longer period, cells were eventually arrested in GO/GlA phase, due to the suppression of G1A "* G1B transition (data not shown). When blast cells were stimulated with IL-3 or GM-CSF, cellular susceptibility to FasR-mediated apoptosis could be induced by an increase of cells entering the G1B compartment, but not by an increase of cells in the S phase. Nonetheless the data from patient W12 in Fig 2 were most puzzling. It is difficult to understand why DNA synthesis in the presence of anti-Fas MoAb and cytokines dropped below the level of Fas-insensitive spontaneous DNA synthesis. It might be postulated that IL-3 and GM-CSF could directly accelerate FasR-mediated signal transduction, resulting in the induction of apoptosis, regardless of a phase of the cell cycle. Further studies are necessary to clarify whether these cytokines might have any stimulatory effect on intracellular transduction of FasR-triggered signals.
The second messenger systems used by FasR-mediated signals are still poorly characterized." It has been suggested that the product of proto-oncogene bcl-2 might interfere with the apoptotic process mediated by FasR c r o s~-l i n k i n g~~*~ It is, however, unlikely that bcl-2 expression is associated with the survival and sensitivity to anti-Fas MoAb in MML-1 cells, because bcl-2 protein is not induced in MML-l cells arrested in the G1A phase. The present observations are more consistent with the concept that signal transduction of It is worthwhile to investigate whether apoptotic signaling through FasR could activate an acidic SMase in asynchronously growing MML-l cells, but not in cells arrested in the G1A phase with PMA and thymidine. Apparently G l A -+ G l B transition in the cell cycle is necessary, but not fully enough for the induction of FasR-mediated apoptosis, because we have also established a FasR', apoptosis-insensitive cell line, MML-1R from the same patient. Recently, it has been described that IL-3-mediated cell survival was linked with the induction of cyclin D2, D3, E, and cyclin-dependent kinase 4.48 It is also worthwhile to study the correlation between FasR-mediated apoptosis and induction of G1 cyclin and cyclin-dependent kinases in leu- anti-Fas antibody in therapy is only feasible if the antibody can be targeted specifically to leukemic cells and vital normal tissues remain ~naffected.~' Recently, several investigators have reported that cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways, which are complementary, one based on secretion of lytic proteins and one that depends on cell-surface ligand-receptor interaction?2353 Activated T cells expressing FasL could exert Fas-dependent lysis of target leukemic cells, although FasL-based killing activity might be functionally directed to the target cells mostly in the G1B compartment. The induction of apoptosis in the Fas system by activated cytotoxic T cells might provide an alternative strategy for the treatment of AML.
